Nvidia opens BioNeMo to scale digital biology for global biopharma

Nvidia (NVDA) announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA BioNeMo Framework to advance drug discovery and accelerate molecule design. Researchers require specialized biomolecular models and datasets that allow them to gather insights at scale to design therapeutics faster. The open-source BioNeMo Framework offers a collection of accelerated computing tools designed to exponentially scale AI models for biomolecular research, bringing a new level of supercomputing to biopharma. “The convergence of AI, accelerated computing and expanding datasets offers unprecedented opportunities for the pharmaceutical industry, as evidenced by recent Nobel Prize wins in chemistry,” said Kimberly Powell, vice president of healthcare at NVIDIA. “To help unravel the complexities of biological systems, we’ve introduced the open-source BioNeMo Framework, which will enable researchers worldwide to accelerate the development of life-saving treatments.”